Increased availability of central benzodiazepine receptors in patients with chronic hepatic encephalopathy and alcohol related cirrhosis

Gut

Volumn 46, Issue 4, 2000, Pages 546-552

  Jalan, R ^a   Turjanski, N ^a   Taylor Robinson, S D ^a   Koepp, M J ^a   Richardson, M P ^a   Wilson, J A ^a   Bell, J D ^a   Brooks, D J ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

11C flumazenil; Benzodiazepine receptors; Chronic hepatic encephalopathy; In vivo proton magnetic resonance spectroscopy; Positron emission tomography

Indexed keywords

BENZODIAZEPINE RECEPTOR;

ADULT; AGED; ALCOHOL LIVER CIRRHOSIS; ARTICLE; BASAL GANGLION; BRAIN CORTEX; BRAIN METABOLISM; CEREBELLUM; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HEPATIC ENCEPHALOPATHY; HUMAN; MALE; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECEPTOR BINDING;

ADULT; AGED; BRAIN; CASE-CONTROL STUDIES; FEMALE; HEPATIC ENCEPHALOPATHY; HUMANS; LIVER CIRRHOSIS, ALCOHOLIC; MAGNETIC RESONANCE SPECTROSCOPY; MALE; MIDDLE AGED; RECEPTORS, GABA-A; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0034080696     PISSN: 00175749     EISSN: None     Source Type: Journal    
DOI: 10.1136/gut.46.4.546     Document Type: Article

References (43)

1. 1 Gitlin N, Lewis DC, Hinkley L. The diagnosis and prevalence of subclinical hepatic encephalopathy in apparently healthy ambulant non-shunted patients with cirrhosis. J Hepatol 1986;3:375-82.
2. 2 Conn HO. Assessment of the severity of hepatic encephalopathy. In: Rodes J, Arroyo V, eds. Therapy in liver diseases. Barcelona: Ediciones Doyma, 1992:277-91.
3. 1H MR spectroscopy. Radiology 1992;182:19-27.
4. 4 Ross BD, Jacobsen S, Villamil F, et al. Subclinical hepatic encephalopathy: proton MR spectroscopic abnormalities. Radiology 1994;193:457-63.
5. 5 Taylor-Robinson SD, Sargentoni J, Marcus CD, et al. Regional variations in cerebral proton spectroscopy in with chronic hepatic encephalopathy. Metab Brain Dis 1994;9: 347-59.
6. 6 Ross BD, Danielsen ER, Bluml S. Proton magnetic resonance spectroscopy: the new gold standard for diagnosis of clinical and subclinical hepatic encephalopathy. Dig Dis 1996;14:30-9.
7. 7 Ferenci P, Herneth A, Puspok A, et al. Neuropharmacologic modulation of hepatic encephalopathy: experimental and clinical data. Adv Exp Med Biol 1994;368:103-12.
8. 8 Butterworth RF. Hepatic encephalopathy: a disorder of multiple neurotransmitter systems. In: Record CO, Al Mardini H, eds. Advances in hepatic encephalopathy and metabolism in liver diseases. Newcastle: Medical Faculty of the University of Newcastle, 1997:167-76.
9. 9 Olsen RW, Tobin AJ. Molecular biology of GABA(A) receptors. FASEB J 1990;4:1469-80.
10. 10 Jones EA, Basile AS, Skolnick P. Hepatic encephalopathy, GABA-ergic neurotransmission and benzodiazepine receptor ligands. Adv Exp Med Biol 1990;272:121-34.
11. 11 Basile AS, Hughes RD, Harrison PM, et al. Elevated brain concentrations of 1,4-benzodiazepines in fulminant hepatic failure. N Engl J Med 1991;325:473-8.
12. 12 Bakti G, Fisch HU, Karlaganis G, Minder C, Bircher J. Mechanism of the excessive sedative response of cirrhotics to benzodiazepines: model experiments with triazolam. Hepatology 1987;7:629-38.
13. 13 Ferenci P, Herneth A, Steindl P. Newer approaches to therapy of hepatic encephalopathy. Semin Liv Dis 1996;16: 329-38.
14. A receptor subunit mRNAs in the rat brain. 1. Telencephalon, diencephalon, mesencephalon. J Neurosci 1992;12:1040-62.
15. 11C): a special radioligand for the in vivo study of central benziodiazepine receptors by positron emission tomography. Int J Appl Radiat Isot 1984;35:973-6.
16. 16 Conn HO, Leevy CM, Vlahcevic ZR, et al. Comparison of lactulose and neomycin in the treatment of chronic portal-systemic encephalopathy: a double blind trial. Gastroenterology 1977;72:573-83.
17. 17 Wechsler D. Wechsler adult intelligence scale manual. New York: Psychological Corporation, 1955.
18. 18 Kendrick DC, Gibson AJ, Moyes IC. The revised Kendrick battery: clinical studies. Br J Soc Clin Psychol 1979;18:329-39.
19. 19 Pugh RNH, Murray-Lyon IM, Dawson JL, et al. Transection of the oesophagus for bleeding oesophageal varices. Br J Surg 1973;60:646-9.
20. 20 Spinks TJ, Jones T, Gilardi MC, et al. Physical performance of the latest generation of commercial positron scanners. IEEE Trans Nucl Sci 1988;35:721-5.
21. 21 Ranicar ASO, Williams CW, Schnorr L, et al. The on-line monitoring of continuously withdrawn arterial blood during PET studies using a single BGO/photomultiplier assembly and non-stick tubing. Med Prog Technol 1991;17: 259-64.
22. 11C]-SCH23390. J Label Compound Radiopharm 1993;32: 518-20.
23. 11C]deprenyl and dynamic positron emission tomography. J Cereb Blood Flow Metab 1991;11:545-56.
24. 24 Friston KJ, Ashburner J, Poline JB, et al. Spatial registration and normalization of images. Hum Brain Mapping 1996;2: 165-89.
25. 25 Cunningham VJ, Jones T. Spectral analysis of dynamic PET studies. J Cereb Blood Flow Metab 1993;13:15-23.
26. 11C]flumazenil and PET: application of the steady-state principle. J Cereb Blood Flow Metab 1995;15:152-65.
27. 27 Robb RA, Hanson DP. A software system for interactive and quantitative visualization of multidimensional biomedical images. Australasian Phys Engin Sci Med 1991;19:9-30.
28. 28 Basile AS, Jones EA, Skolnick P. The pathogenesis and treatment of hepatic encephalopathy: evidence for the involvement of benzodiazepine receptor ligands. Pharmacol Rev 1991;43:27-71.
29. 29 Basile AS, Pannell L, Jaouni T, et al. Brain concentrations of benzodiazepines are elevated in an animal model of hepatic encephalopathy. Proc Natl Acad Sci USA 1990;87:5263-7.
30. 30 Mullen KD, Szauter KM, Kaminsky-Russ K. Endogenous benzodiazepine activity in body fluids of patients with hepatic encephalopathy. Lancet 1990;336:81-3.
31. 11C]RO15-1788, a benzodiazepine antagonist, studied in human brain in vivo by positron tomography. Eur J Pharmacol 1985;110:247-51.
32. 32 MacDonald GA, Frey KA, Agranoff BA, et al. Cerebral benzodiazepine receptor binding in vivo in patients with recurrent hepatic encephalopathy. Hepatology 1997;26: 277-82.
33. 33 Mhatre M, Mehta AK, Ticku MK. Chronic ethanol administration increases the binding of the benzodiazepine inverse agonist and alcohol antagonist [3H]RO15-4513 in rat brain. Eur J Pharmacol 1988;153:141-5.
34. A receptor gene expression by ethanol in the rat hippocampus versus cerebral cortex. J Neurochem 1998;70:1160-6.
35. A receptors in the acute and chronic effects of ethanol. Psychopharmacology (Berl) 1998;139:2-19.
36. 11C-flumazenil. Psychopharmacology (Berl) 1992;107:180-5.
37. 37 Farde L, Pauli S, Litton JE, et al. PET-derermination of benzodiazepine receptor binding in studies on alcoholism. EXS 1994;71:143-53.
38. A-benzodiazepine receptor in alcohol dependency in the absence of grey matter atrophy. Br J Psychiatry 1998;173:116-22.
39. 39 Taylor-Robinson SD, Sargentoni J, Oatridge A, et al. MR imaging and spectroscopy of the basal ganglia in chronic liver disease: Correlation of T, weighted contrast measurements with abnormalities in proton and phosphorus-31 MR spectra. Metab Brain Dis 1906;11:249-68.
40. 40 Taylor-Robinson SD, Buckley C, Changani KK, et al. Cerebral proton and phosphorus-31 magnetic resonance spectroscopy in patients with subclinical hepatic encephalopathy. Liver 1999;19:389-98.
41. 41 Chamuleau RA, Bosman DK, Bovee WMMJ, et al. What the clinician can learn from MR glutamine/glutamate assays. NMR Biomed 1991;4:103-8.
42. 42 Laubenberger J, Haussinger D, Bayer S, et al. Proton magnetic resonance spectroscopy of the brain in symptomatic and asymptomatic patients with liver cirrhosis. Gastroenterology 1997;112:1610-16.
43. 43 Butterworth RF, Giguere JF, Michaud J, et al. Ammonia: key factor in the pathogencsis of hepatic encephalopathy. Neurochem Pathol 1987;6:1-12.